Impact of FDA's Recent Draft Guidance on Participant Diversity

In this second of two parts on the developing participant diversity movement, sponsor, CRO and site representatives discuss the impact of the FDA's recent draft guidance and the efforts they already are making to increase inclusivity in their trials.